In a recent interview with PharmaShots, Peony Yu, Chief Medical Officer of FibroGen shared her insights and highlights on data of RoxadustatShots:FibroGen presented new efficacy and safety analyses from the roxadustat global P-III program at ASN Kidney Week 2020 Reimagined. FibroGen and its partners, AstraZeneca and Astellas, presented 42 abstracts, including 2 late-breaker poster presentations,…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…
In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company.Shots:The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical's InPen to the Medtronic portfolio, as of Sept'2020The…
In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on the launch of CODEai.Shots:CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences extensive catalog of molecular data with cancer treatment information and clinical outcomes data for ~215,000…
In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Executive Officer of True Digital Surgery shared his insights and highlights on data of the Aesculap Aeos Robotic Digital Microscope.Shots:The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and ear, nose, and throat operations, through a multi-axis robotic arm.The platform utilizes…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itLife sciences companies are putting all of their efforts into finding a treatment or developing a vaccine for this diseasePharmaShots is keeping a track of all of the important updates in the Life-sciences…
The US FDA has approved 4 NDAs and 1 BLA in Oct 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 90 novel products so far in 2020, including 5 in Oct 2020.…
In a recent interview with PharmaShots, Dr. Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences shares her insights and highlights on data of Ongentys.Shots:In a post-hoc, sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD…
In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020.Shots:All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyDuring the month of October, Henlius signed two agreements for its biosimilar products and presented results of HLX03 (biosimilar, adalimumab) whereas Samsung Bioepis and Biogen announced EMA filing acceptance of SB11 (biosimilar, ranibizumab)Our team at PharmaShots…

